Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.82 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | RAD52 | P43351 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.82 |
| ▸ | HTR2A | P28223 | 6/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.82 |
| ▸ | HRH1 | P35367 | 6/20 | 0.82 |
| ▸ | DRD3 | P35462 | 6/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL30903938 | 1.00 | MAPT (1.00) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL10891828 | 0.95 | MAPT (0.90) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL15511012 | 0.94 | MAPT (0.89) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL29089279 | 0.94 | MAPT (0.89) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL1527298 | 0.94 | MAPT (0.89) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL14126977 | 0.91 | DRD2 (1.00) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL18429 | 0.91 | DRD2 (1.00) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL29369439 | 0.91 | DRD2 (1.00) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Prochlorperazine SCHEMBL29358207 | 0.91 | DRD2 (1.00) | MAPTMAPK1CYP3A4TP53RAD52 | |
| Perazine SCHEMBL7654455 | 0.91 | CYP3A4 (0.82) | MAPTMAPK1CYP3A4TP53RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344506-B2 | Rapidly disintegrating oral dissolvable film | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2022-05-31 | — | — | US | claimed |
| US-20220008334-A1 | GASTRIC RETENTIVE DEVICES | CLEXIO BIOSCIENCES LTD. (IL) | 2022-01-13 | — | — | US | claimed |
| US-11147766-B2 | Gastric retentive devices | CLEXIO BIOSCIENCES LTD. (IL) | 2021-10-19 | — | — | US | claimed |
| US-10617682-B2 | Preservative-free prochlorperazine nasal spray for migraine therapy | ROSEMAN UNIVERSITY OF HEALTH SCIENCES (US) | 2020-04-14 | — | — | US | claimed |
| US-20180344720-A1 | PRESERVATIVE-FREE PROCHLORPERAZINE NASAL SPRAY FOR MIGRAINE THERAPY | ROSEMAN UNIVERSITY OF HEALTH SCIENCES | 2018-12-06 | — | — | US | claimed |
| US-10100362-B2 | Schizophrenia-associated genetic loci identified in genome wide association studies and methods of use thereof | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2018-10-16 | — | — | US | claimed |
| US-20160032390-A1 | SCHIZOPHRENIA-ASSOCIATED GENETIC LOCI IDENTIFIED IN GENOME WIDE ASSOCIATION STUDIES AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2016-02-04 | — | — | US | claimed |
| EP-2767275-A1 | Nortriptyline, haloperidol or prochlorperazine edisylate for use in the treatment of tuberculosis as well as two screening methods | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-08-20 | — | — | EP | claimed |
| US-8679535-B2 | Sustained release matrix systems for highly soluble drugs | ENDO PHARMACEUTICALS INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-8524665-B2 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20070185018-A1 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1233761-B1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND COATS | ALZA CORP (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004100899-A2 | USE OF SECRETIN IN TREATMENTS OF DISORDERS ASSOCIATED WITH THE AMYGDALA | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| EP-1233761-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND COATS | ALZA Corporation (US) | 2002-08-28 | — | — | EP | claimed |
| WO-2001037815-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND | ALZA CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |